Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease

Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease

Source: 
Fierce Biotech
snippet: 

Ionis Pharmaceuticals has dropped more data on its AstraZeneca-partnered treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), shedding a little more light on how the antisense candidate matches up to Alnylam’s incumbents.